Clofarabine-induced kidney toxicity

Journal of Oncology Pharmacy Practice

Volumn 20, Issue 4, 2014, Pages 305-308

  Jhaveri, Kenar D ^a   Chidella, Shailaja ^a   Allen, Steven L ^a   Fishbane, Steven ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Acute renal failure; Clofarabine; Proteinuria; Renal toxicity

Indexed keywords

ADENINE NUCLEOTIDE; ARABINONUCLEOSIDE; CLOFARABINE;

ACUTE KIDNEY FAILURE; ACUTE MYELOID LEUKEMIA; ANIMAL; CASE REPORT; CHEMICALLY INDUCED; HUMAN; MALE; MIDDLE AGED; PROTEINURIA;

ACUTE KIDNEY INJURY; ADENINE NUCLEOTIDES; ANIMALS; ARABINONUCLEOSIDES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROTEINURIA;

EID: 84905645606     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155213504976     Document Type: Article

References (14)

1. http://www.clolar.com/-/media/Files/Clolar/prescribinginformation.pdf (accessed 23 January 2013).
2. Ghanem H, Kantarjian H, Ohanian M, et al. The role of clofarabine in acute myeloid leukemia. Leuk Lymphoma 2013; 54(4): 688-698.
3. Zhenchuk A, Lotfi K, Juliusson G, et al. Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol 2009; 78: 1351-1359.
4. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Surveillance/AdverseDrugEffects/default.htm. (accessed 23 January 2013).
5. Kintzel PE, Visser JA and Campbell AD. Clofarabineassociated acute kidney injury and proteinuria. Pharmacotherapy 2011; 31: 923.
6. http://www.cancer.gov/cancertopics/pdq/supportivecare/ gastrointestinalcomplications/HealthProfessional/Table1. (accessed 23 January 2013).
7. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010; 28: 549-555.
8. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28: 2389-2395.
9. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006; 108: 45-51.
10. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and highrisk myelodysplastic syndrome. Blood 2008; 112: 1638-1645.
11. National Comprehensive Cancer Network. AML Guidelines, www.nccn.org (accessed 16 August 2013).
12. Elledge SJ, Zhou Z and Allen JB. Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem Sci 1992; 17: 119-123.
13. Powell DR, Desai U, Sparks MJ, et al. Rapid development of glomerular injury and renal failure in mice lacking p53R2. Pediatr Nephrol 2005; 20: 432-440.
14. Kimura T, Takeda S, Sagiya Y, et al. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 2003; 34: 440-445.